09633180

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSSPTA1613SXW

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS 1		Web Page URLs for STN Seminar Schedule - N. America
NEWS 2	Jan 25	BLAST(R) searching in REGISTRY available in STN on the Web
NEWS 3	Jan 29	FSTA has been reloaded and moves to weekly updates
NEWS 4	Feb 01	DKILIT now produced by FIZ Karlsruhe and has a new update frequency
NEWS 5	Feb 19	Access via Tymnet and SprintNet Eliminated Effective 3/31/02
NEWS 6	Mar 08	Gene Names now available in BIOSIS
NEWS 7	Mar 22	TOXLIT no longer available
NEWS 8	Mar 22	TRCTHERMO no longer available
NEWS 9	Mar 28	US Provisional Priorities searched with P in CA/CAplus and USPATFULL
NEWS 10	Mar 28	LIPINSKI/CALC added for property searching in REGISTRY
NEWS 11	Apr 02	PAPERCHEM no longer available on STN. Use PAPERCHEM2 instead.
NEWS 12	Apr 08	"Ask CAS" for self-help around the clock
NEWS 13	Apr 09	BEILSTEIN: Reload and Implementation of a New Subject Area
NEWS 14	Apr 09	ZDB will be removed from STN
NEWS 15	Apr 19	US Patent Applications available in IFICDB, IFIPAT, and IFIUDB
NEWS 16	Apr 22	Records from IP.com available in CAPLUS, HCAPLUS, and ZCAPLUS
NEWS 17	Apr 22	BIOSIS Gene Names now available in TOXCENTER
NEWS 18	Apr 22	Federal Research in Progress (FEDRIP) now available

NEWS EXPRESS	February 1 CURRENT WINDOWS VERSION IS V6.0d, CURRENT MACINTOSH VERSION IS V6.0a(ENG) AND V6.0Ja(JP), AND CURRENT DISCOVER FILE IS DATED 05 FEBRUARY 2002
NEWS HOURS	STN Operating Hours Plus Help Desk Availability
NEWS INTER	General Internet Information
NEWS LOGIN	Welcome Banner and News Items
NEWS PHONE	Direct Dial and Telecommunication Network Access to STN
NEWS WWW	CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 13:55:34 ON 29 MAY 2002

09633180

=>
Uploading 633180c.str

L1 STRUCTURE UPLOADED

=> d
L1 HAS NO ANSWERS
L1 STR



G1 C,O

Structure attributes must be viewed using STN Express query preparation.

=> s l1 sss sam
SAMPLE SEARCH INITIATED 19:29:43 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 5182 TO ITERATE

19.3% PROCESSED 1000 ITERATIONS 1 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 99327 TO 107953
PROJECTED ANSWERS: 1 TO 239

L2 1 SEA SSS SAM L1

=> s l1 full
FULL SEARCH INITIATED 19:29:51 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 107715 TO ITERATE

100.0% PROCESSED 107715 ITERATIONS 75 ANSWERS
SEARCH TIME: 00.00.14

L3 75 SEA SSS FUL L1

09633180

=> fil caplus
COST IN U.S. DOLLARS

	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	140.66	140.87

FILE 'CAPLUS' ENTERED AT 19:30:10 ON 29 MAY 2002
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907 - 29 May 2002 VOL 136 ISS 22
FILE LAST UPDATED: 27 May 2002 (20020527/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

CAS roles have been modified effective December 16, 2001. Please check your SDI profiles to see if they need to be revised. For information on CAS roles, enter HELP ROLES at an arrow prompt or use the CAS Roles thesaurus (/RL field) in this file.

=> s l3 full
L4 52 L3

09633180

```
=> s l4 and pge?
         33466 PGE?
L8           1 L4 AND PGE?

=> d l8 ibib abs hitstr

L8   ANSWER 1 OF 1  CAPLUS  COPYRIGHT 2002 ACS
ACCESSION NUMBER:        1982:406057  CAPLUS
DOCUMENT NUMBER:         97:6057
TITLE:                   Carbacyclin analogs
INVENTOR(S):             Aristoff, Paul Adrian; Kelly, Robert Charles; Nelson,
                         Norman Allan
PATENT ASSIGNEE(S):      Upjohn Co., USA
SOURCE:                  Brit. UK Pat. Appl., 79 pp.
                         CODEN: BAXXDU
DOCUMENT TYPE:           Patent
LANGUAGE:                English
FAMILY ACC. NUM. COUNT:  4
PATENT INFORMATION:
```

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
GB 2070596	A	19810909	GB 1981-2901	19810130
GB 2070596	B2	19840208		
US 4338457	A	19820706	US 1980-125608	19800228
CA 1201712	A1	19860311	CA 1981-368710	19810116
IL 61936	A1	19860831	IL 1981-61936	19810120
IL 73113	A1	19860831	IL 1981-73113	19810120
AU 8166606	A1	19810903	AU 1981-66606	19810123
AU 542861	B2	19850321		
SE 8100564	A	19810829	SE 1981-564	19810128
SE 453594	B	19880215		
SE 453594	C	19880526		
DE 3105588	A1	19811210	DE 1981-3105588	19810216
DE 3105588	C2	19890413		
DE 3153390	C2	19890914	DE 1981-3153390	19810216
DE 3153474	C2	19900531	DE 1981-3153474	19810216
DE 3153460	C2	19900816	DE 1981-3153460	19810216
CH 648017	A	19850228	CH 1981-1038	19810217
CH 655308	A	19860415	CH 1984-1786	19810217
BE 887721	A1	19810827	BE 1981-203954	19810227
NL 8100959	A	19811001	NL 1981-959	19810227
FR 2484413	A1	19811218	FR 1981-3965	19810227
FR 2484413	B1	19860523		
JP 56138130	A2	19811028	JP 1981-27697	19810228
JP 03055458	B4	19910823		
GB 2121802	A1	19840104	GB 1983-19029	19830714
GB 2121802	B2	19850116		
GB 2122201	A1	19840111	GB 1983-19030	19830714
GB 2122201	B2	19841205		
GB 2122202	A1	19840111	GB 1983-19031	19830714
GB 2122202	B2	19850103		
GB 2122203	A1	19840111	GB 1983-19032	19830714
GB 2122203	B2	19850103		
CA 1313670	A2	19930216	CA 1983-440031	19831028
AU 8538208	A1	19850620	AU 1985-38208	19850130
AU 567392	B2	19871119		
SE 8504615	A	19851004	SE 1985-4615	19851004
SE 8504616	A	19851004	SE 1985-4616	19851004
SE 8504617	A	19851004	SE 1985-4617	19851004

SE 8504618	A	19851004	SE 1985-4618	19851004
SE 8504619	A	19851004	SE 1985-4619	19851004
JP 02167248	A2	19900627	JP 1989-275132	19891024
JP 04008427	B4	19920217		
JP 06145085	A2	19940524	JP 1993-25993	19930122

PRIORITY APPLN. INFO.:

US 1980-125608	19800228
US 1980-135055	19800328
US 1980-140546	19800415
US 1980-142953	19800423
CA 1981-368710	19810116
IL 1981-61936	19810120
GB 1981-2901	19810130
CH 1981-1038	19810217

OTHER SOURCE(S): CASREACT 97:6057

GI



I



II

AB The prepn. is reported of the novel carbacyclin analogs I and II (R1 = H, R2 = H, alkyl, R3 = H, F; R1R2 = methylene; when R-R2 = H, R4 = phenylene; n, R, R5-R11 = substituents std. in prostaglandin art), which inhibit platelet aggregation, reduce gastric secretion, inhibit NOSAC-induced lesion, and are antiasthma agents (no data). E.g., the known 3-oxa-1,2,4,5,6-pentanor-3,7-inter-m-phenylene-**PGE1** 3-(tert-butyldimethylsilyl ether) 11,15-bis(tetrahydropyranyl ether) was converted to II [R = OH, R5 = CH:CHCH(OH)(CH2)4Me, R6 = .beta.-H, R7-R10 = H, R11 = CH2CO2H] in 9 steps, and itself converted to other carbacyclins.

IT **76794-01-9P 81845-41-2P 81845-45-6P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation)
(prepn. and cyclization of)

RN 76794-01-9 CAPLUS

CN Phosphonic acid, [2-oxo-3-[5-oxo-3-[(tetrahydro-2H-pyran-2-yl)oxy]-2-[3-[(tetrahydro-2H-pyran-2-yl)oxy]-1-octenyl]cyclopentyl]propyl]-, dimethyl ester, [1R-[1.alpha.,2.beta.(1E,3S*),3.alpha.]]- (9CI) (CA INDEX NAME)



RN 81845-41-2 CAPLUS
CN Phosphonic acid, [2-oxo-4-[5-oxo-3-[(tetrahydro-2H-pyran-2-yl)oxy]-2-[3-[(tetrahydro-2H-pyran-2-yl)oxy]-1-octenyl]cyclopentyl]butyl]-, dimethyl ester, [1R-[1.alpha.,2.beta.(1E,S*),3.alpha.]]- (9CI) (CA INDEX NAME)



RN 81845-45-6 CAPLUS
CN Phosphonic acid, [3-[2-[[[(1,1-dimethylethyl)dimethylsilyl]oxy]methyl]-5-oxo-3-[(tetrahydro-2H-pyran-2-yl)oxy]cyclopentyl]-2-oxopropyl]-, dimethyl ester, [1R-(1.alpha.,2.beta.,3.alpha.)]- (9CI) (CA INDEX NAME)



09633180

=> s l4 and prostaglandin?
68127 PROSTAGLANDIN?
L15 11 L4 AND PROSTAGLANDIN?

=> d l15 1-11 ibib abs hitstr

L15 ANSWER 1 OF 11 CAPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER: 1994:671652 CAPLUS
DOCUMENT NUMBER: 121:271652
TITLE: Syntheses of new TXA2/PGH2-receptor antagonists and their biological properties
AUTHOR(S): Deicke, P; Klar, U.
CORPORATE SOURCE: Res. Lab., Schering AG, Berlin, W-1000/65, Germany
SOURCE: Bioorg. Med. Chem. Lett. (1992), 2(9), 1063-8
CODEN: BMCLE8; ISSN: 0960-894X
DOCUMENT TYPE: Journal
LANGUAGE: English
AB The syntheses of new types of TXA2/PGH2-receptor antagonists and some structure activity relationships are discussed. It is shown that a suitable substituent attached directly to the carbon bridge of the 2-oxabicyclo[2.2.1]heptane system of the std. TXA2/PGH2-receptor agonist U 46619 changes the biol. profile from an agonist to an antagonist and results in biol. very active compds.
IT **151049-92-2P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation)
(prepn. and cyclization of)
RN 151049-92-2 CAPLUS
CN Phosphonic acid, [3-[2-[[[(1,1-dimethylethyl)diphenylsilyl]oxy]methyl]-5-oxo-3-[(tetrahydro-2H-pyran-2-yl)oxy]cyclopentyl]-2-oxopropyl]-, dimethyl ester, [1R-(1.alpha.,2.beta.,3.alpha.)]- (9CI) (CA INDEX NAME)



L15 ANSWER 2 OF 11 CAPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER: 1988:150081 CAPLUS
DOCUMENT NUMBER: 108:150081
TITLE: Synthesis of a carbaprostacyclin intermediate - 6.beta.-[(tert-butyldimethylsiloxy)methyl]-7-.alpha.-[(tetrahydropyran-2-yl)oxy]bicyclo[3.3.0]octan-3-one
AUTHOR(S): Liu, Zhiyu; He, Xuchang; Yang, Jiying; Wang, Heqian
CORPORATE SOURCE: Shanghai Inst. Org. Chem., Acad. Sin., Shanghai, Peop. Rep. China
SOURCE: Huaxue Xuebao (1987), 45(7), 727-9
CODEN: HHHPA4; ISSN: 0567-7351
DOCUMENT TYPE: Journal
LANGUAGE: Chinese
OTHER SOURCE(S): CASREACT 108:150081

09633180

GI



I



II

AB The title compd. (I; R = 2-tetrahydropyranyl) was prepd. in 7 steps starting from lactone II.

IT **113566-82-8P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation)
(prepn. and intramol. Wittig-Horner reaction of)

RN 113566-82-8 CAPLUS

L15 ANSWER 3 OF 11 CAPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER: 1984:454789 CAPLUS
DOCUMENT NUMBER: 101:54789
TITLE: Carbacyclin analogs
INVENTOR(S): Aristoff, Paul A.
PATENT ASSIGNEE(S): Upjohn Co. , USA
SOURCE: U.S., 50 pp. Cont.-in-part of U.S. Ser. No. 140,547, abandoned.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 4420632	A	19831213	US 1980-219175	19801222
US 4525586	A	19850625	US 1983-533489	19830919
PRIORITY APPLN. INFO.:			US 1980-140547	19800415
			US 1980-219175	19801222

OTHER SOURCE(S): CASREACT 101:54789
GI



I



II

AB Title compds. (I) (R = C1-5 alkyl; n = 1, 2; Q, Z, R1-3 = groups assocd. with **prostaglandins**) were prepd. by appropriate modifications of conventional methods. Typical of compds. prepd. was II.

IT **76794-01-9P 81845-41-2P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation)
(prepn. and cyclization of)

RN 76794-01-9 CAPLUS
CN Phosphonic acid, [2-oxo-3-[5-oxo-3-[(tetrahydro-2H-pyran-2-yl)oxy]-2-[3-[(tetrahydro-2H-pyran-2-yl)oxy]-1-octenyl]cyclopentyl]propyl]-, dimethyl ester, [1R-[1.alpha.,2.beta.(1E,3S*),3.alpha.]]- (9CI) (CA INDEX NAME)



RN 81845-41-2 CAPLUS
CN Phosphonic acid, [2-oxo-4-[5-oxo-3-[(tetrahydro-2H-pyran-2-yl)oxy]-2-[3-[(tetrahydro-2H-pyran-2-yl)oxy]-1-octenyl]cyclopentyl]butyl]-, dimethyl ester, [1R-[1.alpha.,2.beta.(1E,S*),3.alpha.]]- (9CI) (CA INDEX NAME)



IT **81845-45-6P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation)
(prepn. and reaction with (carboxybutyl)triphenylphosphonium bromide)

RN 81845-45-6 CAPLUS
CN Phosphonic acid, [3-[2-[[[(1,1-dimethylethyl)dimethylsilyl]oxy]methyl]-5-oxo-3-[(tetrahydro-2H-pyran-2-yl)oxy]cyclopentyl]-2-oxopropyl]-, dimethyl ester, [1R-(1.alpha.,2.beta.,3.alpha.)]- (9CI) (CA INDEX NAME)



L15 ANSWER 4 OF 11 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 1984:22452 CAPLUS
DOCUMENT NUMBER: 100:22452
TITLE: Synthesis of 9-substituted carbacyclin analogs
AUTHOR(S): Aristoff, Paul A.; Johnson, Paul D.; Harrison, Allen W.
CORPORATE SOURCE: Upjohn Co., Kalamazoo, MI, 49001, USA
SOURCE: J. Org. Chem. (1983), 48(26), 5341-8
CODEN: JOCEAH; ISSN: 0022-3263
DOCUMENT TYPE: Journal
LANGUAGE: English
GI



I



II

AB A series of 9-substituted carbacyclin analogs with potent platelet antiaggregatory activity was prepd. The key step for the formation of 9-acetylene compds. (e.g., I) utilized a modification of the Schwartz procedure involving the Ni-catalyzed conjugate addn. of the appropriate alkynyl aluminate to II. 9-Methylcarbacyclin could be prepd. by a similar procedure. A novel alternative to the Wittig reaction for introducing the carbacyclin upper side chain in base-sensitive substrates involved addn. of the dianion of Me3CSiMe2O(CH2)5CO2H to the appropriate ketone (e.g., II), followed by decarboxylative dehydration of the resulting .beta.-hydroxy acid.

IT **76794-01-9P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation)
(prepn. and cyclization of)
RN 76794-01-9 CAPLUS
CN Phosphonic acid, [2-oxo-3-[5-oxo-3-[(tetrahydro-2H-pyran-2-yl)oxy]-2-[3-[(tetrahydro-2H-pyran-2-yl)oxy]-1-octenyl]cyclopentyl]propyl]-, dimethyl ester, [1R-[1.alpha.,2.beta.(1E,3S*),3.alpha.]]- (9CI) (CA INDEX NAME)



L15 ANSWER 5 OF 11 CAPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER: 1983:89049 CAPLUS
DOCUMENT NUMBER: 98:89049
TITLE: Methanocarbacyclin analogs
INVENTOR(S): Aristoff, Paul A.
PATENT ASSIGNEE(S): Upjohn Co. , USA
SOURCE: U.S., 50 pp.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 4349689	A	19820914	US 1980-219106	19801222

GI



AB I (n = 1 or 2; R, R1, R2, R3, A, Q are groups assocd. with **prostaglandins**; R4 = H or Me) were prepd. by appropriate modifications of conventional methods and shown to inhibit platelet

aggregation and have antihypertensive activity. Typical of compds. prepd. was II.

IT **81845-45-6P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation)
(prepn. and sapon. of)

RN 81845-45-6 CAPLUS

CN Phosphonic acid, [3-[2-[[[(1,1-dimethylethyl)dimethylsilyl]oxy]methyl]-5-oxo-3-[(tetrahydro-2H-pyran-2-yl)oxy]cyclopentyl]-2-oxopropyl]-, dimethyl ester, [1R-(1.alpha.,2.beta.,3.alpha.)]- (9CI) (CA INDEX NAME)



L15 ANSWER 6 OF 11 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 1982:406057 CAPLUS
DOCUMENT NUMBER: 97:6057
TITLE: Carbacyclin analogs
INVENTOR(S): Aristoff, Paul Adrian; Kelly, Robert Charles; Nelson, Norman Allan
PATENT ASSIGNEE(S): Upjohn Co., USA
SOURCE: Brit. UK Pat. Appl., 79 pp.
CODEN: BAXXDU
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 4
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
GB 2070596	A	19810909	GB 1981-2901	19810130
GB 2070596	B2	19840208		
US 4338457	A	19820706	US 1980-125608	19800228
CA 1201712	A1	19860311	CA 1981-368710	19810116
IL 61936	A1	19860831	IL 1981-61936	19810120
IL 73113	A1	19860831	IL 1981-73113	19810120
AU 8166606	A1	19810903	AU 1981-66606	19810123
AU 542861	B2	19850321		
SE 8100564	A	19810829	SE 1981-564	19810128
SE 453594	B	19880215		
SE 453594	C	19880526		
DE 3105588	A1	19811210	DE 1981-3105588	19810216
DE 3105588	C2	19890413		
DE 3153390	C2	19890914	DE 1981-3153390	19810216
DE 3153474	C2	19900531	DE 1981-3153474	19810216
DE 3153460	C2	19900816	DE 1981-3153460	19810216
CH 648017	A	19850228	CH 1981-1038	19810217
CH 655308	A	19860415	CH 1984-1786	19810217
BE 887721	A1	19810827	BE 1981-203954	19810227
NL 8100959	A	19811001	NL 1981-959	19810227

FR 2484413	A1	19811218	FR 1981-3965	19810227
FR 2484413	B1	19860523		
JP 56138130	A2	19811028	JP 1981-27697	19810228
JP 03055458	B4	19910823		
GB 2121802	A1	19840104	GB 1983-19029	19830714
GB 2121802	B2	19850116		
GB 2122201	A1	19840111	GB 1983-19030	19830714
GB 2122201	B2	19841205		
GB 2122202	A1	19840111	GB 1983-19031	19830714
GB 2122202	B2	19850103		
GB 2122203	A1	19840111	GB 1983-19032	19830714
GB 2122203	B2	19850103		
CA 1313670	A2	19930216	CA 1983-440031	19831028
AU 8538208	A1	19850620	AU 1985-38208	19850130
AU 567392	B2	19871119		
SE 8504615	A	19851004	SE 1985-4615	19851004
SE 8504616	A	19851004	SE 1985-4616	19851004
SE 8504617	A	19851004	SE 1985-4617	19851004
SE 8504618	A	19851004	SE 1985-4618	19851004
SE 8504619	A	19851004	SE 1985-4619	19851004
JP 02167248	A2	19900627	JP 1989-275132	19891024
JP 04008427	B4	19920217		
JP 06145085	A2	19940524	JP 1993-25993	19930122

PRIORITY APPLN. INFO.:

US 1980-125608	19800228
US 1980-135055	19800328
US 1980-140546	19800415
US 1980-142953	19800423
CA 1981-368710	19810116
IL 1981-61936	19810120
GB 1981-2901	19810130
CH 1981-1038	19810217

OTHER SOURCE(S): CASREACT 97:6057

GI



I



II

AB The prepn. is reported of the novel carbacyclin analogs I and II (R1 = H, R2 = H, alkyl, R3 = H, F; R1R2 = methylene; when R-R2 = H, R4 = phenylene; n, R, R5-R11 = substituents std. in **prostaglandin** art), which inhibit platelet aggregation, reduce gastric secretion, inhibit NOSAC-induced lesion, and are antiasthma agents (no data). E.g., the known 3-oxa-1,2,4,5,6-pentanor-3,7-inter-m-phenylene-PGE1 3-(tert-butyldimethylsilyl ether) 11,15-bis(tetrahydropyranyl ether) was converted to II [R = OH, R5 = CH:CHCH(OH)(CH2)4Me, R6 = .beta.-H, R7-R10 = H, R11 = CH2CO2H] in 9 steps, and itself converted to other carbacyclins.

IT **76794-01-9P 81845-41-2P 81845-45-6P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation)
(prepn. and cyclization of)

RN 76794-01-9 CAPLUS
CN Phosphonic acid, [2-oxo-3-[5-oxo-3-[(tetrahydro-2H-pyran-2-yl)oxy]-2-[3-[(tetrahydro-2H-pyran-2-yl)oxy]-1-octenyl]cyclopentyl]propyl]-, dimethyl ester, [1R-[1.alpha.,2.beta.(1E,3S*),3.alpha.]]- (9CI) (CA INDEX NAME)



RN 81845-41-2 CAPLUS
CN Phosphonic acid, [2-oxo-4-[5-oxo-3-[(tetrahydro-2H-pyran-2-yl)oxy]-2-[3-[(tetrahydro-2H-pyran-2-yl)oxy]-1-octenyl]cyclopentyl]butyl]-, dimethyl ester, [1R-[1.alpha.,2.beta.(1E,S*),3.alpha.]]- (9CI) (CA INDEX NAME)



RN 81845-45-6 CAPLUS
CN Phosphonic acid, [3-[2-[[[(1,1-dimethylethyl)dimethylsilyl]oxy]methyl]-5-oxo-3-[(tetrahydro-2H-pyran-2-yl)oxy]cyclopentyl]-2-oxopropyl]-, dimethyl ester, [1R-(1.alpha.,2.beta.,3.alpha.)]- (9CI) (CA INDEX NAME)



L15 ANSWER 7 OF 11 CAPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER: 1982:162422 CAPLUS
DOCUMENT NUMBER: 96:162422
TITLE: Prostacyclin analogs
INVENTOR(S): Aristoff, Paul A.
PATENT ASSIGNEE(S): Upjohn Co. , USA
SOURCE: U.S., 51 pp. Cont.-in-part of U.S. Ser. No. 135,055, abandoned.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 4
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 4306075	A	19811215	US 1980-219210	19801222
IL 73113	A1	19860831	IL 1981-73113	19810120
CH 655308	A	19860415	CH 1984-1786	19810217
CA 1313670	A2	19930216	CA 1983-440031	19831028

PRIORITY APPLN. INFO.:

US 1980-135055	19800328
US 1980-125608	19800228
US 1980-140546	19800415
US 1980-142953	19800423
CA 1981-368710	19810116
IL 1981-61936	19810120
CH 1981-1038	19810217

GI



I



II

AB A series of .apprx.150 carbaprostacyclin analogs, and intermediates for them, was prepd. by appropriate modifications of conventional methods. Typical compds. prepd. and specifically claimed were I and II.

IT **81168-24-3P 81203-92-1P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation)
(prepn. and cyclization of)
RN 81168-24-3 CAPLUS
CN Phosphonic acid, [2-oxo-4-[5-oxo-3-[(tetrahydro-2H-pyran-2-yl)oxy]-2-[3-[(tetrahydro-2H-pyran-2-yl)oxy]-1-octenyl]cyclopentyl]butyl]-, dimethyl ester, [1.alpha.,2.beta.(1E,3S*),3.alpha.]- (9CI) (CA INDEX NAME)



RN 81203-92-1 CAPLUS
CN Phosphonic acid, [2-oxo-3-[5-oxo-3-[(tetrahydro-2H-pyran-2-yl)oxy]-2-[3-[(tetrahydro-2H-pyran-2-yl)oxy]-1-octenyl]cyclopentyl]propyl]-, dimethyl ester, [1.alpha.,2.beta.(1E,3S*),3.alpha.]- (9CI) (CA INDEX NAME)



IT **81168-53-8P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation)
(prepn. and sapon. of)
RN 81168-53-8 CAPLUS
CN Phosphonic acid, [3-[2-[[[(1,1-dimethylethyl)dimethylsilyl]oxy]methyl]-5-oxo-3-[(tetrahydro-2H-pyran-2-yl)oxy]cyclopentyl]-2-oxopropyl]-, dimethyl ester, (1.alpha.,2.beta.,3.alpha.)- (9CI) (CA INDEX NAME)





L15 ANSWER 8 OF 11 CAPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER: 1982:162421 CAPLUS
DOCUMENT NUMBER: 96:162421
TITLE: Inter-phenylene CBA compounds
INVENTOR(S): Nelson, Norman A.
PATENT ASSIGNEE(S): Upjohn Co. , USA
SOURCE: U.S., 51 pp. Cont.-in-part of U.S. Ser. No. 142,953, abandoned.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 4
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 4306076	A	19811215	US 1980-219131	19801222
IL 73113	A1	19860831	IL 1981-73113	19810120
CH 655308	A	19860415	CH 1984-1786	19810217
CA 1313670	A2	19930216	CA 1983-440031	19831028
PRIORITY APPLN. INFO.:			US 1980-142953	19800423
			US 1980-125608	19800228
			US 1980-135055	19800328
			US 1980-140546	19800415
			CA 1981-368710	19810116
			IL 1981-61936	19810120
			CH 1981-1038	19810217

GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB A series of .apprx.150 carbaprostacyclin analogs, and intermediates for them, was prepd. by appropriate modifications by conventional methods. Typical compds. prepd. and specifically claimed were I and II.

IT **81168-24-3P 81168-53-8P 81203-92-1P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation)
(prepn. and cyclization of)

RN 81168-24-3 CAPLUS

CN Phosphonic acid, [2-oxo-4-[5-oxo-3-[(tetrahydro-2H-pyran-2-yl)oxy]-2-[3-[(tetrahydro-2H-pyran-2-yl)oxy]-1-octenyl]cyclopentyl]butyl]-, dimethyl ester, [1.alpha.,2.beta.(1E,3S*),3.alpha.]- (9CI) (CA INDEX NAME)



RN 81168-53-8 CAPLUS
CN Phosphonic acid, [3-[2-[[[(1,1-dimethylethyl)dimethylsilyl]oxy]methyl]-5-oxo-3-[(tetrahydro-2H-pyran-2-yl)oxy]cyclopentyl]-2-oxopropyl]-, dimethyl ester, (1.alpha.,2.beta.,3.alpha.)- (9CI) (CA INDEX NAME)





RN 81203-92-1 CAPLUS
CN Phosphonic acid, [2-oxo-3-[5-oxo-3-[(tetrahydro-2H-pyran-2-yl)oxy]-2-[3-[(tetrahydro-2H-pyran-2-yl)oxy]-1-octenyl]cyclopentyl]propyl]-, dimethyl ester, [1.alpha.,2.beta.(1E,3S*),3.alpha.]- (9CI) (CA INDEX NAME)



09633180

L15 ANSWER 9 OF 11 CAPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER: 1981:208411 CAPLUS
DOCUMENT NUMBER: 94:208411
TITLE: Practical synthesis of 6a-carbaprostaglandin I2
AUTHOR(S): Aristoff, Paul A.
CORPORATE SOURCE: Exp. Chem. Res., Upjohn Co., Kalamazoo, MI, 49001, USA
SOURCE: J. Org. Chem. (1981), 46(9), 1954-7
CODEN: JOCEAH; ISSN: 0022-3263
DOCUMENT TYPE: Journal
LANGUAGE: English
GI



I



II

AB An efficient synthesis of 6a-carbaprostaglandin I2 (I), a stable analog of prostacyclin, was described utilizing a novel intramol. Wadsworth-Emmons reaction of the key intermediate II.

IT **76794-01-9P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation)
(prepn. and cyclization of)

RN 76794-01-9 CAPLUS

CN Phosphonic acid, [2-oxo-3-[5-oxo-3-[(tetrahydro-2H-pyran-2-yl)oxy]-2-[3-[(tetrahydro-2H-pyran-2-yl)oxy]-1-octenyl]cyclopentyl]propyl]-, dimethyl ester, [1R-[1.alpha.,2.beta.(1E,3S*),3.alpha.]]- (9CI) (CA INDEX NAME)



L15 ANSWER 10 OF 11 CAPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER: 1981:191740 CAPLUS
DOCUMENT NUMBER: 94:191740
TITLE: The synthesis of dimethylphosphonoprostaglandin analogs
AUTHOR(S): Kluender, Harold C.; Woessner, Warren
CORPORATE SOURCE: Miles Lab., Inc., Madison, WI, 53704, USA
SOURCE: Prostaglandins Med. (1979), 2(6), 441-4
CODEN: PROMDL; ISSN: 0161-4630
DOCUMENT TYPE: Journal
LANGUAGE: English
AB Several known title compds. were prepd. conventionally.
IT **72488-19-8P 72488-20-1P 72522-51-1P 72522-52-2P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of)
RN 72488-19-8 CAPLUS
CN Phosphonic acid, [6-[2-(3-hydroxy-1-octenyl)-5-oxocyclopentyl]hexyl]-, dimethyl ester, [1R-[1.alpha.,2.beta.(1E,3S*)]]- (9CI) (CA INDEX NAME)



RN 72488-20-1 CAPLUS
CN Phosphonic acid, [(8.beta.,12.alpha.,13E,15S)-15-hydroxy-9-oxoprost-13-en-1-yl]-, dimethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 72522-51-1 CAPLUS
CN Phosphonic acid, [6-[2-(3-hydroxy-1-octenyl)-5-oxocyclopentyl]hexyl]-, dimethyl ester, [1S-[1.alpha.,2.beta.(1E,3R*)]]- (9CI) (CA INDEX NAME)



RN 72522-52-2 CAPLUS
CN Phosphonic acid, [(13E,15S)-15-hydroxy-9-oxoprost-13-en-1-yl]-, dimethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



L15 ANSWER 11 OF 11 CAPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER: 1980:58302 CAPLUS
DOCUMENT NUMBER: 92:58302
TITLE: 1 and 2-Substituted analogs of certain **prostaglandins**
INVENTOR(S): Biddlecom, William G.; Kluender, Harold C.; Woessner, Warren D.
PATENT ASSIGNEE(S): Miles Laboratories, Inc., USA
SOURCE: U.S., 40 pp.
CODEN: USXXAM
DOCUMENT TYPE: Patent

09633180

LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 4171331	A	19791016	US 1978-912515	19780605

GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB App. 110 decarboxyprostaglandin analogs and intermediates for them were prepd. from the key compds. I (n = 6,7) by appropriate modifications of conventional syntheses; extensive biol. activity tests (inhibition of platelet aggregation, and gastric secretion, antihyprotensive and muscle relaxant activity) were carried out. Among the compds. prepd. were II-V.

IT **72488-19-8P 72488-20-1P 72522-51-1P**
72522-52-2P
RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(prepn. and biol. activity of)

RN 72488-19-8 CAPLUS
CN Phosphonic acid, [6-[2-(3-hydroxy-1-octenyl)-5-oxocyclopentyl]hexyl]-, dimethyl ester, [1R-[1.alpha.,2.beta.(1E,3S*)]]- (9CI) (CA INDEX NAME)



RN 72488-20-1 CAPLUS
CN Phosphonic acid, [(8.beta.,12.alpha.,13E,15S)-15-hydroxy-9-oxoprost-13-en-1-yl]-, dimethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 72522-51-1 CAPLUS

CN Phosphonic acid, [6-[2-(3-hydroxy-1-octenyl)-5-oxocyclopentyl]hexyl]-, dimethyl ester, [1S-[1.alpha.,2.beta.(1E,3R*)]]- (9CI) (CA INDEX NAME)



RN 72522-52-2 CAPLUS
CN Phosphonic acid, [(13E,15S)-15-hydroxy-9-oxoprost-13-en-1-yl]-, dimethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



09633180

```
=> fil reg
COST IN U.S. DOLLARS                                  SINCE FILE      TOTAL
                                                        ENTRY     SESSION
                                                         0.21        0.21
FULL ESTIMATED COST

FILE 'REGISTRY' ENTERED AT 13:55:42 ON 29 MAY 2002
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2002 American Chemical Society (ACS)

STRUCTURE FILE UPDATES:   27 MAY 2002  HIGHEST RN 422267-53-6
DICTIONARY FILE UPDATES:  27 MAY 2002  HIGHEST RN 422267-53-6

TSCA INFORMATION NOW CURRENT THROUGH July 7, 2001

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

Crossover limits have been increased.  See HELP CROSSOVER for details.

Calculated physical property data is now available.  See HELP PROPERTIES
for more information.  See STNote 27, Searching Properties in the CAS
Registry File, for complete details:
http://www.cas.org/ONLINE/STN/STNOTES/stnotes27.pdf

=>
Uploading 633180b.str

L1      STRUCTURE UPLOADED

=> d
L1 HAS NO ANSWERS
L1                STR
```



o/c

```
Structure attributes must be viewed using STN Express query preparation.


=> s l1 sss sam
SAMPLE SEARCH INITIATED 13:55:59 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -     13 TO ITERATE

100.0% PROCESSED      13 ITERATIONS                                0 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE  **COMPLETE**
                        BATCH   **COMPLETE**
```

09633180

PROJECTED ITERATIONS: 44 TO 476
PROJECTED ANSWERS: 0 TO 0

L2 0 SEA SSS SAM L1

=> s l1 full
FULL SEARCH INITIATED 13:56:03 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 301 TO ITERATE

100.0% PROCESSED 301 ITERATIONS 2 ANSWERS
SEARCH TIME: 00.00.01

L3 2 SEA SSS FUL L1

=> fil caplus

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	140.28	140.49

FILE 'CAPLUS' ENTERED AT 13:56:09 ON 29 MAY 2002
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907 - 29 May 2002 VOL 136 ISS 22
FILE LAST UPDATED: 27 May 2002 (20020527/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

CAS roles have been modified effective December 16, 2001. Please check your SDI profiles to see if they need to be revised. For information on CAS roles, enter HELP ROLES at an arrow prompt or use the CAS Roles thesaurus (/RL field) in this file.

=> s l3 full
L4 2 L3

=> d l4 1-2 ibib abs hitstr

L4 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER: 1981:191740 CAPLUS
DOCUMENT NUMBER: 94:191740
TITLE: The synthesis of dimethylphosphonoprostaglandin analogs
AUTHOR(S): Kluender, Harold C.; Woessner, Warren
CORPORATE SOURCE: Miles Lab., Inc., Madison, WI, 53704, USA
SOURCE: Prostaglandins Med. (1979), 2(6), 441-4
CODEN: PROMDL; ISSN: 0161-4630

09633180

DOCUMENT TYPE: Journal
LANGUAGE: English
AB Several known title compds. were prepd. conventionally.
IT **72488-19-8P 72522-51-1P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of)
RN 72488-19-8 CAPLUS
CN Phosphonic acid, [6-[2-(3-hydroxy-1-octenyl)-5-oxocyclopentyl]hexyl]-, dimethyl ester, [1R-[1.alpha.,2.beta.(1E,3S*)]]- (9CI) (CA INDEX NAME)



RN 72522-51-1 CAPLUS
CN Phosphonic acid, [6-[2-(3-hydroxy-1-octenyl)-5-oxocyclopentyl]hexyl]-, dimethyl ester, [1S-[1.alpha.,2.beta.(1E,3R*)]]- (9CI) (CA INDEX NAME)



L4 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER: 1980:58302 CAPLUS
DOCUMENT NUMBER: 92:58302
TITLE: 1 and 2-Substituted analogs of certain prostaglandins
INVENTOR(S): Biddlecom, William G.; Kluender, Harold C.; Woessner, Warren D.
PATENT ASSIGNEE(S): Miles Laboratories, Inc., USA
SOURCE: U.S., 40 pp.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 4171331	A	19791016	US 1978-912515	19780605

GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB App. 110 decarboxyprostaglandin analogs and intermediates for them were prepd. from the key compds. I (n = 6,7) by appropriate modifications of conventional syntheses; extensive biol. activity tests (inhibition of platelet aggregation, and gastric secretion, antihyprotensive and muscle relaxant activity) were carried out. Among the compds. prepd. were II-V.

IT **72488-19-8P 72522-51-1P**
RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(prepn. and biol. activity of)

RN 72488-19-8 CAPLUS
CN Phosphonic acid, [6-[2-(3-hydroxy-1-octenyl)-5-oxocyclopentyl]hexyl]-, dimethyl ester, [1R-[1.alpha.,2.beta.(1E,3S*)]]- (9CI) (CA INDEX NAME)



RN 72522-51-1 CAPLUS
CN Phosphonic acid, [6-[2-(3-hydroxy-1-octenyl)-5-oxocyclopentyl]hexyl]-, dimethyl ester, [1S-[1.alpha.,2.beta.(1E,3R*)]]- (9CI) (CA INDEX NAME)



09633180

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSSPTA1613SXW

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS 1		Web Page URLs for STN Seminar Schedule - N. America
NEWS 2	Jan 25	BLAST(R) searching in REGISTRY available in STN on the Web
NEWS 3	Jan 29	FSTA has been reloaded and moves to weekly updates
NEWS 4	Feb 01	DKILIT now produced by FIZ Karlsruhe and has a new update frequency
NEWS 5	Feb 19	Access via Tymnet and SprintNet Eliminated Effective 3/31/02
NEWS 6	Mar 08	Gene Names now available in BIOSIS
NEWS 7	Mar 22	TOXLIT no longer available
NEWS 8	Mar 22	TRCTHERMO no longer available
NEWS 9	Mar 28	US Provisional Priorities searched with P in CA/CAplus and USPATFULL
NEWS 10	Mar 28	LIPINSKI/CALC added for property searching in REGISTRY
NEWS 11	Apr 02	PAPERCHEM no longer available on STN. Use PAPERCHEM2 instead.
NEWS 12	Apr 08	"Ask CAS" for self-help around the clock
NEWS 13	Apr 09	BEILSTEIN: Reload and Implementation of a New Subject Area
NEWS 14	Apr 09	ZDB will be removed from STN
NEWS 15	Apr 19	US Patent Applications available in IFICDB, IFIPAT, and IFIUDB
NEWS 16	Apr 22	Records from IP.com available in CAPLUS, HCAPLUS, and ZCAPLUS
NEWS 17	Apr 22	BIOSIS Gene Names now available in TOXCENTER
NEWS 18	Apr 22	Federal Research in Progress (FEDRIP) now available

NEWS EXPRESS	February 1 CURRENT WINDOWS VERSION IS V6.0d, CURRENT MACINTOSH VERSION IS V6.0a(ENG) AND V6.0Ja(JP), AND CURRENT DISCOVER FILE IS DATED 05 FEBRUARY 2002
NEWS HOURS	STN Operating Hours Plus Help Desk Availability
NEWS INTER	General Internet Information
NEWS LOGIN	Welcome Banner and News Items
NEWS PHONE	Direct Dial and Telecommunication Network Access to STN
NEWS WWW	CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

* * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 13:53:27 ON 29 MAY 2002

09633180

```
=> fil reg
COST IN U.S. DOLLARS                                    SINCE FILE      TOTAL
                                                           ENTRY    SESSION
FULL ESTIMATED COST                                         0.21       0.21

FILE 'REGISTRY' ENTERED AT 13:53:45 ON 29 MAY 2002
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2002 American Chemical Society (ACS)

STRUCTURE FILE UPDATES:   27 MAY 2002  HIGHEST RN 422267-53-6
DICTIONARY FILE UPDATES:  27 MAY 2002  HIGHEST RN 422267-53-6

TSCA INFORMATION NOW CURRENT THROUGH July 7, 2001

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

Crossover limits have been increased.  See HELP CROSSOVER for details.

Calculated physical property data is now available.  See HELP PROPERTIES
for more information.  See STNote 27, Searching Properties in the CAS
Registry File, for complete details:
http://www.cas.org/ONLINE/STN/STNOTES/stnotes27.pdf

=>
Uploading 09633180.str

L1      STRUCTURE UPLOADED

=> d
L1 HAS NO ANSWERS
L1                STR
```




```
Structure attributes must be viewed using STN Express query preparation.


=> s l1 sss sam
SAMPLE SEARCH INITIATED 13:54:04 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -      8 TO ITERATE

100.0% PROCESSED       8 ITERATIONS                                 0 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE  **COMPLETE**
                        BATCH   **COMPLETE**
```

09633180

PROJECTED ITERATIONS: 8 TO 329
PROJECTED ANSWERS: 0 TO 0

L2 0 SEA SSS SAM L1

=> s l1 full
FULL SEARCH INITIATED 13:54:09 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 219 TO ITERATE

100.0% PROCESSED 219 ITERATIONS 0 ANSWERS
SEARCH TIME: 00.00.01

L3 0 SEA SSS FUL L1

09633180

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSSPTA1613SXW

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS 1		Web Page URLs for STN Seminar Schedule - N. America
NEWS 2	Jan 25	BLAST(R) searching in REGISTRY available in STN on the Web
NEWS 3	Jan 29	FSTA has been reloaded and moves to weekly updates
NEWS 4	Feb 01	DKILIT now produced by FIZ Karlsruhe and has a new update frequency
NEWS 5	Feb 19	Access via Tymnet and SprintNet Eliminated Effective 3/31/02
NEWS 6	Mar 08	Gene Names now available in BIOSIS
NEWS 7	Mar 22	TOXLIT no longer available
NEWS 8	Mar 22	TRCTHERMO no longer available
NEWS 9	Mar 28	US Provisional Priorities searched with P in CA/CAplus and USPATFULL
NEWS 10	Mar 28	LIPINSKI/CALC added for property searching in REGISTRY
NEWS 11	Apr 02	PAPERCHEM no longer available on STN. Use PAPERCHEM2 instead.
NEWS 12	Apr 08	"Ask CAS" for self-help around the clock
NEWS 13	Apr 09	BEILSTEIN: Reload and Implementation of a New Subject Area
NEWS 14	Apr 09	ZDB will be removed from STN
NEWS 15	Apr 19	US Patent Applications available in IFICDB, IFIPAT, and IFIUDB
NEWS 16	Apr 22	Records from IP.com available in CAPLUS, HCAPLUS, and ZCAPLUS
NEWS 17	Apr 22	BIOSIS Gene Names now available in TOXCENTER
NEWS 18	Apr 22	Federal Research in Progress (FEDRIP) now available

NEWS EXPRESS	February 1 CURRENT WINDOWS VERSION IS V6.0d, CURRENT MACINTOSH VERSION IS V6.0a(ENG) AND V6.0Ja(JP), AND CURRENT DISCOVER FILE IS DATED 05 FEBRUARY 2002
NEWS HOURS	STN Operating Hours Plus Help Desk Availability
NEWS INTER	General Internet Information
NEWS LOGIN	Welcome Banner and News Items
NEWS PHONE	Direct Dial and Telecommunication Network Access to STN
NEWS WWW	CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 14:25:41 ON 29 MAY 2002

09633180

```
=> fil reg
COST IN U.S. DOLLARS                                    SINCE FILE      TOTAL
                                                           ENTRY    SESSION
                                                            0.21       0.21
FULL ESTIMATED COST

FILE 'REGISTRY' ENTERED AT 14:25:52 ON 29 MAY 2002
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2002 American Chemical Society (ACS)

STRUCTURE FILE UPDATES:   27 MAY 2002  HIGHEST RN 422267-53-6
DICTIONARY FILE UPDATES:  27 MAY 2002  HIGHEST RN 422267-53-6

TSCA INFORMATION NOW CURRENT THROUGH July 7, 2001

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

Crossover limits have been increased.  See HELP CROSSOVER for details.

Calculated physical property data is now available.  See HELP PROPERTIES
for more information.  See STNote 27, Searching Properties in the CAS
Registry File, for complete details:
http://www.cas.org/ONLINE/STN/STNOTES/stnotes27.pdf

=> prostaglandin E
PROSTAGLANDIN IS NOT A RECOGNIZED COMMAND
The previous command name entered was not recognized by the system.
For a list of commands available to you in the current file, enter
"HELP COMMANDS" at an arrow prompt (=>).

=> s prostaglandin E
          1020 PROSTAGLANDIN
        582872 E
L1          54 PROSTAGLANDIN E
               (PROSTAGLANDIN(W)E)

=> fil caplus
COST IN U.S. DOLLARS                                    SINCE FILE      TOTAL
                                                           ENTRY    SESSION
                                                            8.38       8.59
FULL ESTIMATED COST

FILE 'CAPLUS' ENTERED AT 14:26:29 ON 29 MAY 2002
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2002 AMERICAN CHEMICAL SOCIETY (ACS)
```


FILE COVERS 1907 - 29 May 2002 VOL 136 ISS 22

09633180

FILE LAST UPDATED: 27 May 2002 (20020527/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

CAS roles have been modified effective December 16, 2001. Please check your SDI profiles to see if they need to be revised. For information on CAS roles, enter HELP ROLES at an arrow prompt or use the CAS Roles thesaurus (/RL field) in this file.

=> s l1 full
L2 272 L1

=> d l2 ibib abs hitstr

L2 ANSWER 1 OF 272 CAPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER: 2002:161635 CAPLUS
DOCUMENT NUMBER: 136:338584
TITLE: Trophic effects of the cyclooxygenase-2 product prostaglandin E2 in cardiac myocytes
AUTHOR(S): Mendez, Mariela; LaPointe, Margot C.
CORPORATE SOURCE: Hypertension and Vascular Research Division, Henry Ford Hospital, Detroit, MI, USA
SOURCE: Hypertension (2002), 39(2, Pt. 2), 382-388
CODEN: HPRTDN; ISSN: 0194-911X
PUBLISHER: Lippincott Williams & Wilkins
DOCUMENT TYPE: Journal
LANGUAGE: English
AB Interleukin-1.beta. (IL-1.beta.), a proinflammatory cytokine, induces cyclooxygenase-2 (COX-2) in cultured neonatal ventricular myocytes (NVMs), resulting in the preferential prodn. of prostaglandin E2 (PGE2). To explain the preferential PGE2 release by myocytes, we studied whether its specific synthase, PGE2 synthase (PGES), is also induced by IL-1.beta.. Because COX-2 has been extensively assocd. with cell growth, we questioned whether PGE2 plays a role in cardiac cell growth. IL-1.beta.-treated myocytes showed induction of PGES protein and mRNA by Western blot and reverse transcription-polymerase chain reaction, resp. Immunofluorescence studies revealed perinuclear localization of COX-2 and PGES in IL-1.beta.-treated myocytes. Exogenous PGE2 increased protein synthesis in NVMs. as indicated by a 1.6-fold increase in [3H]leucine incorporation, comparable to the known hypertrophic factor phenylephrine (1.6-fold). Because PGE2 exerts different effects through 4 receptor subtypes (EP1, EP2, EP3, and EP4), we investigated whether these receptors are functional in myocytes. Treatment of NVMs with the selective EP1/EP3 agonist sulprostone significantly increased protein synthesis (1.7-fold), whereas the EP1/EP2 antagonist AH6809 blocked this effect by 43%. In contrast, AH6809 had no effect on PGE2-induced protein synthesis. Regarding second messengers, sulprostone had no effect on cAMP, whereas PGE2 increased it. We concluded that (1) PGE2 prodn. requires the induction of its specific synthase; (2) in myocytes, the inducible enzymes COX-2 and PGES are perinuclear: and (3) PGE, and sulprostone induce cardiac myocyte growth but seem to activate a different subset of EP receptors.
IT **52227-79-9**, PGE2 synthase
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(IL-1.beta. effect on PGE2 synthase and COX-2 in cardiac myocyte hypertrophy)
RN 52227-79-9 CAPLUS
CN Synthase, prostaglandin E (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

09633180

REFERENCE COUNT: 48 THERE ARE 48 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d l2 2 ibib abs hitstr

L2 ANSWER 2 OF 272 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 2002:108246 CAPLUS
DOCUMENT NUMBER: 136:292564

TITLE: Cyclooxygenase-1 is up-regulated in cervical carcinomas: autocrine/paracrine regulation of cyclooxygenase-2, prostaglandin E receptors, and angiogenic factors by cyclooxygenase-1

AUTHOR(S): Sales, Kurt J.; Katz, Arieh A.; Howard, Bruce; Soeters, Roggert P.; Millar, Robert P.; Jabbour, Henry N.

CORPORATE SOURCE: Department of Medical Biochemistry, University of Cape Town Medical School, Cape Town, 7925, S. Afr.

SOURCE: Cancer Research (2002), 62(2), 424-432
CODEN: CNREA8; ISSN: 0008-5472

PUBLISHER: American Association for Cancer Research
DOCUMENT TYPE: Journal
LANGUAGE: English

AB This study was designed to investigate the expression and mol. signaling of cyclooxygenase-1 (COX-1) in cervical carcinomas. Real-time quant. reverse transcription-polymerase chain reaction and Western blot anal. confirmed enhanced expression of COX-1 RNA, and protein in squamous cell carcinomas and adenocarcinoma of the cervix. COX-1 expression in all carcinoma tissues was assocd. with enhanced expression of COX-2 RNA and protein. The site of COX-1 expression was localized by immunohistochem. to the neoplastic epithelial cells in all squamous cell carcinomas and adenocarcinomas studied. Minimal COX-1 immunoreactivity was detected in normal cervix. To explore events assocd. with COX-1 up-regulation, we developed a doxycycline-regulated expression system in HeLa (cervical carcinoma) cells. Overexpression of COX-1 in HeLa cells resulted in induced expression of cyclooxygenase-2 (COX-2) and prostaglandin E synthase (PGES) concomitant with increased prostaglandin E2 (PGE2) synthesis. Treatment of HeLa cells overexpressing COX-1 with the dual COX enzyme inhibitor indomethacin or selective COX-2 inhibitor NS-398 significantly reduced PGE2 synthesis. Indomethacin, but not NS-398, treatment abolished the up-regulation of expression of COX-2 and PGES in HeLa cells, suggesting that the obsd. up-regulation of COX-2 and PGES was mediated by COX-1-enzyme products. To assess whether enhanced PGE2 synthesis after COX-1 induction would act in an autocrine/paracrine manner, we investigated the effect of COX-1 on the expression of the different isoforms of PGE2 receptors (EP1-EP4). We found that the cAMP-linked PGE2 receptors were significantly up-regulated by COX-1 overexpression coincident with enhanced cAMP responsiveness of these cells to exogenous PGE2 ligand. Finally, overexpression of COX-1 was assocd. with enhanced expression of the angiogenic factors basic fibroblast growth factor, vascular endothelial growth factor, angiopoietin-1, and angiopoietin-2. This up-regulation of angiogenic factor expression was abolished by indomethacin and partially reduced by NS-398. These data indicate that COX-1 up-regulation modulates the expression of factors that may act in an autocrine/paracrine manner to enhance and sustain tumorigenesis in neoplastic cervical epithelial cells. It is likely that similar mechanisms may act in vivo to modulate tumorigenesis of cervical carcinomas.

IT **52227-79-9**, Prostaglandin E synthase
RL: BSU (Biological study, unclassified); BIOL (Biological study)

(cyclooxygenase-1 up-regulation modulates expression of factors that act in autocrine/paracrine manner to enhance and sustain tumorigenesis in neoplastic cervical epithelial cells)
RN 52227-79-9 CAPLUS
CN Synthase, prostaglandin E (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
REFERENCE COUNT: 54 THERE ARE 54 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d l2 3 ibib abs hitstr

L2 ANSWER 3 OF 272 CAPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER: 2001:936497 CAPLUS
DOCUMENT NUMBER: 136:194348
TITLE: Urogenital distribution of a mouse membrane-associated prostaglandin E2 synthase
AUTHOR(S): Guan, Youfei; Zhang, Yahua; Schneider, Andre; Riendeau, Denis; Mancini, Joseph A.; Davis, Linda; Komhoff, Martin; Breyer, Richard M.; Breyer, Matthew D.
CORPORATE SOURCE: Division of Nephrology, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, 37212, USA
SOURCE: American Journal of Physiology (2001), 281(6, Pt. 2), F1173-F1177
CODEN: AJPHAP; ISSN: 0002-9513
PUBLISHER: American Physiological Society
DOCUMENT TYPE: Journal
LANGUAGE: English
AB PGE2 plays a crit. role in regulating renal function and facilitating reprodn. One of the rate-limiting biosynthetic enzymes in PGE2 synthesis is the terminal PGE2 synthase (PGES). In the present studies, the authors report the functional expression of a membrane-assocd. murine PGES (mPGES) and its expression in urogenital tissues. Two independent cDNA clones sharing an identical open reading frame of 459 bp and encoding a peptide of 153 amino acids, but differing in the 3'-untranslated region, were identified. Assays for enzymic activity, using microsomes prepd. from cells transfected with mPGES cDNA, showed that these cDNA sequences encode a functional protein that catalyzes the conversion of PGH2 to PGE2. Constitutive expression of mPGES was highest in the mouse kidney, ovary, and urinary bladder but was also expressed at lower levels in uterus and testis. Renal mPGES expression was predominantly localized to epithelia of distal tubules and medullary collecting ducts. High expression was also seen in transitional epithelial cells of bladder and ureter and in the primary and secondary follicles in the ovary. In conclusion, mPGES is constitutively expressed along the urogenital tract, where it may have important roles in normal physiol. and disease.
IT **400694-97-5**
RL: BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study)
(amino acid sequence; prostaglandin E2 synthase of mouse mol. characterization, urogenital distribution and function)
RN 400694-97-5 CAPLUS
CN Prostaglandin E synthase (Mus musculus kidney) (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
IT **400694-98-6**
RL: BSU (Biological study, unclassified); PRP (Properties); BIOL

09633180

(Biological study)
(nucleotide sequence; prostaglandin E2 synthase of mouse mol. characterization, urogenital distribution and function)
RN 400694-98-6 CAPLUS
CN DNA (Mus musculus kidney prostaglandin E synthase cDNA) (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
IT **52227-79-9**, Prostaglandin E2 synthase
RL: BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study)
(prostaglandin E2 synthase of mouse mol. characterization, urogenital distribution and function)
RN 52227-79-9 CAPLUS
CN Synthase, prostaglandin E (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
REFERENCE COUNT: 21 THERE ARE 21 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d l2 4 ibib abs hitstr

L2 ANSWER 4 OF 272 CAPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER: 2001:888454 CAPLUS
DOCUMENT NUMBER: 136:181537
TITLE: Diversity of gene expression in adenocarcinoma of the lung
AUTHOR(S): Garber, Mitchell E.; Troyanskaya, Olga G.; Schluens, Karsten; Petersen, Simone; Thaesler, Zsuzsanna; Pacyna-Gengelbach, Manuela; Van de Rijn, Matt; Rosen, Glenn D.; Perou, Charles M.; Whyte, Richard I.; Altman, Russ B.; Brown, Patrick O.; Botstein, David; Petersen, Iver
CORPORATE SOURCE: Department of Genetics, Stanford University School of Medicine, Stanford, CA, 94305, USA
SOURCE: Proceedings of the National Academy of Sciences of the United States of America (2001), 98(24), 13784-13789
CODEN: PNASA6; ISSN: 0027-8424
PUBLISHER: National Academy of Sciences
DOCUMENT TYPE: Journal
LANGUAGE: English
AB The global gene expression profiles for 67 human lung tumors representing 56 patients were examd. by using 24,000-element cDNA microarrays. Subdivision of the tumors based on gene expression patterns faithfully recapitulated morphol. classification of the tumors into squamous, large cell, small cell, and adenocarcinoma. The gene expression patterns made possible the sub-classification of adenocarcinoma into subgroups that correlated with the degree of tumor differentiation as well as patient survival. Gene expression anal. thus promises to extend and refine std. pathol. anal. The gene list derived in this study was published as supporting information in Materials and Methods at www.pnas.org/cgi/doi/10.1073/pnas.241500798.
IT **52227-79-9**, Prostaglandin E synthase
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(diversity of gene expression in adenocarcinoma and other carcinomas of the lung)
RN 52227-79-9 CAPLUS
CN Synthase, prostaglandin E (9CI) (CA INDEX NAME)

09633180

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
REFERENCE COUNT: 24 THERE ARE 24 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d l2 5 ibib abs hitstr

L2 ANSWER 5 OF 272 CAPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER: 2001:863716 CAPLUS
DOCUMENT NUMBER: 136:98206
TITLE: Mini review article: Inflammation and regeneration
AUTHOR(S): Nakatani, Yoshito; Muraka, Makoto; Kudo, Ichiro
CORPORATE SOURCE: Department of Health Chemistry, School of Pharmaceutical Science, Showa University, Japan
SOURCE: Ensho, Saisei (2001), 21(5), 577-582
CODEN: ENSHCC
PUBLISHER: Nippon Ensho-Saisei Igakkai
DOCUMENT TYPE: Journal; General Review
LANGUAGE: Japanese
AB A review. Prostaglandin E synthase (PGES) catalyzes isomerization of PGH2 to PGE2 which exhibits potent and various biol. activities. Here we report the mol. identification of two distinct glutathione-dependent PGESs, the terminal PGE2-biosynthetic enzymes of the cyclooxygenase (COX) pathway. These PGESs exhibit unique functional coupling with two upstream COX isoenzymes, COX-1 and COX-2. Cytosolic PGES (cPGES), known as p 23, is constitutively and ubiquitously expressed and predominantly converts COX-1-derived PGH2 to PGE2. Microsomal PGES (mPGES), identical to MGST 1 L1, is an inducible perinuclear enzyme that is functionally linked with COX-2 in marked preference to COX-1. Increased supply of arachidonic acid by explosive activation of cytosolic phospholipase A2 allows COX-1 to be coupled with mPGES.
IT **52227-79-9**, Prostaglandin E synthase
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(mini review article: inflammation and regeneration)
RN 52227-79-9 CAPLUS
CN Synthase, prostaglandin E (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

=> d l2 6 ibib hitstr

L2 ANSWER 6 OF 272 CAPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER: 2001:820776 CAPLUS
DOCUMENT NUMBER: 136:322934
TITLE: Expression of COX-2 and PGE synthase and synthesis of PGE2 in endometrial adenocarcinoma: a possible autocrine/paracrine regulation of neoplastic cell function via EP2/EP4 receptors
AUTHOR(S): Jabbour, H. N.; Milne, S. A.; Williams, A. R. W.; Anderson, R. A.; Boddy, S. C.
CORPORATE SOURCE: MRC Human Reproductive Sciences Unit, Centre for Reproductive Biology, Edinburgh, EH3 9ET, UK
SOURCE: British Journal of Cancer (2001), 85(7), 1023-1031
CODEN: BJCAAI; ISSN: 0007-0920
PUBLISHER: Harcourt Publishers Ltd.
DOCUMENT TYPE: Journal
LANGUAGE: English
IT **52227-79-9**, PGE synthase
RL: BSU (Biological study, unclassified); BIOL (Biological study)

09633180

(COX-2, PGE synthase and PGE2 role in regulating endometrial adenocarcinoma cell function in an autocrine/paracrine manner via EP2/EP4 receptors)
RN 52227-79-9 CAPLUS
CN Synthase, prostaglandin E (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
REFERENCE COUNT: 37 THERE ARE 37 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d l2 7 ibib hitstr

L2 ANSWER 7 OF 272 CAPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER: 2001:817851 CAPLUS
DOCUMENT NUMBER: 136:80202
TITLE: Up-regulation of endothelial cyclooxygenase-2 and prostanoid synthesis by platelets. Role of thromboxane A2
AUTHOR(S): Caughey, Gillian E.; Cleland, Leslie G.; Gamble, Jennifer R.; James, Michael J.
CORPORATE SOURCE: Rheumatology Unit, Royal Adelaide Hospital, Adelaide, 5000, Australia
SOURCE: Journal of Biological Chemistry (2001), 276(41), 37839-37845
CODEN: JBCHA3; ISSN: 0021-9258
PUBLISHER: American Society for Biochemistry and Molecular Biology
DOCUMENT TYPE: Journal
LANGUAGE: English
IT **52227-79-9**, PGE synthase
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(TXA2 role in mechanism for up-regulation of endothelial cyclooxygenase-2 and prostanoid synthesis by platelets)
RN 52227-79-9 CAPLUS
CN Synthase, prostaglandin E (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
REFERENCE COUNT: 44 THERE ARE 44 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

09633180

=> s l4 and pge?
33466 PGE?
L8 1 L4 AND PGE?

=> d l8 ibib abs hitstr

L8 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER: 1982:406057 CAPLUS
DOCUMENT NUMBER: 97:6057
TITLE: Carbacyclin analogs
INVENTOR(S): Aristoff, Paul Adrian; Kelly, Robert Charles; Nelson, Norman Allan
PATENT ASSIGNEE(S): Upjohn Co., USA
SOURCE: Brit. UK Pat. Appl., 79 pp.
CODEN: BAXXDU
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 4
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
GB 2070596	A	19810909	GB 1981-2901	19810130
GB 2070596	B2	19840208		
US 4338457	A	19820706	US 1980-125608	19800228
CA 1201712	A1	19860311	CA 1981-368710	19810116
IL 61936	A1	19860831	IL 1981-61936	19810120
IL 73113	A1	19860831	IL 1981-73113	19810120
AU 8166606	A1	19810903	AU 1981-66606	19810123
AU 542861	B2	19850321		
SE 8100564	A	19810829	SE 1981-564	19810128
SE 453594	B	19880215		
SE 453594	C	19880526		
DE 3105588	A1	19811210	DE 1981-3105588	19810216
DE 3105588	C2	19890413		
DE 3153390	C2	19890914	DE 1981-3153390	19810216
DE 3153474	C2	19900531	DE 1981-3153474	19810216
DE 3153460	C2	19900816	DE 1981-3153460	19810216
CH 648017	A	19850228	CH 1981-1038	19810217
CH 655308	A	19860415	CH 1984-1786	19810217
BE 887721	A1	19810827	BE 1981-203954	19810227
NL 8100959	A	19811001	NL 1981-959	19810227
FR 2484413	A1	19811218	FR 1981-3965	19810227
FR 2484413	B1	19860523		
JP 56138130	A2	19811028	JP 1981-27697	19810228
JP 03055458	B4	19910823		
GB 2121802	A1	19840104	GB 1983-19029	19830714
GB 2121802	B2	19850116		
GB 2122201	A1	19840111	GB 1983-19030	19830714
GB 2122201	B2	19841205		
GB 2122202	A1	19840111	GB 1983-19031	19830714
GB 2122202	B2	19850103		
GB 2122203	A1	19840111	GB 1983-19032	19830714
GB 2122203	B2	19850103		
CA 1313670	A2	19930216	CA 1983-440031	19831028
AU 8538208	A1	19850620	AU 1985-38208	19850130
AU 567392	B2	19871119		
SE 8504615	A	19851004	SE 1985-4615	19851004
SE 8504616	A	19851004	SE 1985-4616	19851004
SE 8504617	A	19851004	SE 1985-4617	19851004

09633180

SE 8504618	A	19851004	SE 1985-4618	19851004
SE 8504619	A	19851004	SE 1985-4619	19851004
JP 02167248	A2	19900627	JP 1989-275132	19891024
JP 04008427	B4	19920217		
JP 06145085	A2	19940524	JP 1993-25993	19930122

PRIORITY APPLN. INFO.:

US 1980-125608	19800228
US 1980-135055	19800328
US 1980-140546	19800415
US 1980-142953	19800423
CA 1981-368710	19810116
IL 1981-61936	19810120
GB 1981-2901	19810130
CH 1981-1038	19810217

OTHER SOURCE(S): CASREACT 97:6057

GI



I



II

AB The prepn. is reported of the novel carbacyclin analogs I and II (R1 = H, R2 = H, alkyl, R3 = H, F; R1R2 = methylene; when R-R2 = H, R4 = phenylene; n, R, R5-R11 = substituents std. in prostaglandin art), which inhibit platelet aggregation, reduce gastric secretion, inhibit NOSAC-induced lesion, and are antiasthma agents (no data). E.g., the known 3-oxa-1,2,4,5,6-pentanor-3,7-inter-m-phenylene-**PGE1** 3-(tert-butyldimethylsilyl ether) 11,15-bis(tetrahydropyranyl ether) was converted to II [R = OH, R5 = CH:CHCH(OH)(CH2)4Me, R6 = .beta.-H, R7-R10 = H, R11 = CH2CO2H] in 9 steps, and itself converted to other carbacyclins.

IT **76794-01-9P 81845-41-2P 81845-45-6P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation)
(prepn. and cyclization of)

RN 76794-01-9 CAPLUS

CN Phosphonic acid, [2-oxo-3-[5-oxo-3-[(tetrahydro-2H-pyran-2-yl)oxy]-2-[3-[(tetrahydro-2H-pyran-2-yl)oxy]-1-octenyl]cyclopentyl]propyl]-, dimethyl ester, [1R-[1.alpha.,2.beta.(1E,3S*),3.alpha.]]- (9CI) (CA INDEX NAME)



RN 81845-41-2 CAPLUS
CN Phosphonic acid, [2-oxo-4-[5-oxo-3-[(tetrahydro-2H-pyran-2-yl)oxy]-2-[3-[(tetrahydro-2H-pyran-2-yl)oxy]-1-octenyl]cyclopentyl]butyl]-, dimethyl ester, [1R-[1.alpha.,2.beta.(1E,S*),3.alpha.]]- (9CI) (CA INDEX NAME)



RN 81845-45-6 CAPLUS
CN Phosphonic acid, [3-[2-[[[(1,1-dimethylethyl)dimethylsilyl]oxy]methyl]-5-oxo-3-[(tetrahydro-2H-pyran-2-yl)oxy]cyclopentyl]-2-oxopropyl]-, dimethyl ester, [1R-(1.alpha.,2.beta.,3.alpha.)]- (9CI) (CA INDEX NAME)